1.
Bioorg Med Chem Lett
; 18(20): 5487-92, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-18815031
RESUMO
An imidazole series of cyclin-dependent kinase (CDK) inhibitors has been developed. Protein inhibitor structure determination has provided an understanding of the emerging structure activity trends for the imidazole series. The introduction of a methyl sulfone at the aniline terminus led to a more orally bioavailable CDK inhibitor that was progressed into clinical development.